
Pfizer has announced a partnership with German biotech firm BioNTech after signing a multi-year deal worth $425 million to develop …

MSD’s experimental drug rVSV-ZEBOV will be used in tackling the latest Ebola outbreak in the Democratic Republic of Congo, after …

San Diego-based biopharma firm Vical has announced the disappointing, if unsurprising, news that it has taken the decision to terminate …

One of the major challenges in delivering vaccinations to all parts of the globe is the need to keep the …

One of the largest petitions ever to have gone before UK parliament, after it attracted 823,349 signatures, brought about the …

The US Centers for Disease Control and Prevention (CDC) has now recommended AstraZeneca’s FluMist as an option for doctors for …

The sometimes poor efficacy of influenza vaccines may be due to poor immune response and a patient’s wider immune history, …

Research led by Georgia State University has enabled the development of a universal vaccine for influenza A viruses, proven to …

Vaccitech, a spin-out company from the University of Oxford, recently launched a Series A financing round and had some fairly …

A team of researchers at the University of Maryland School of Medicine (UMSOM) has been assessing the effectiveness of a …

Seqirus, an influenza vaccine specialist subsidiary of global biotech firm CSL, has announced a £40 million investment into a new …

Eli Lilly has announced it is to partner up with CureVac to leverage its proprietary RNActive technology in order to …

Researchers are enrolling 500 participants for the trial of a flu vaccine to protect the population against all strains of …

Sanofi’s development of a Zika vaccine, alongside the US’s Biomedical Advanced Research and Development Authority (BARDA), has hit the headlines …

The American Diabetes Association 77th Scientific Sessions closed yesterday and one of the most interesting pieces of research to emerge …